Basis: Current FMP quote-based enterprise value / four-quarter operating income. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBIT ratio is N/A as of 2026-10-06T19:08:37.434Z.
Calculation as of: 2026-10-06T19:08:37.434Z.
Quote observation: 2026-10-06T18:53:31.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: cafac005872c57a3e4a0b6cd3f460881363b31539507c7b963fc5044b4159481
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBIT RATIO
N/A
Market Cap
$678241.00
EV/EBIT Ratio
5.81x
TTM Avg
18.06x
3Y Avg
18.06x
5Y Avg
18.06x
Market Cap
$380715.00
EV/EBIT Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$731546.00
EV/EBIT Ratio
N/A
TTM Avg
4890412.78x
3Y Avg
4039256.57x
5Y Avg
4039256.57x
| NAME | MARKET CAP | EV/EBIT RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| VivoSim Labs, Inc. (VIVS) | $530421.00 | N/A | N/A | N/A | N/A |
| HCW Biologics Inc. (HCWB)vs › | $563178.00 | N/A | N/A | N/A | N/A |
| XORTX Therapeutics Inc. (XRTX)vs › | $484571.00 | N/A | N/A | N/A | N/A |
| CDT Equity Inc. (CDT)vs › | $678241.00 | 5.81x | 18.06x | 18.06x | 18.06x |
| Niki BioSolutions, Inc. (NIKI)vs › | $381940.00 | N/A | N/A | N/A | N/A |
| Virax Biolabs Group Limited (VRAX)vs › | $380715.00 | N/A | N/A | N/A | N/A |
| China SXT Pharmaceuticals, Inc. (SXTC)vs › | $731546.00 | N/A | 4890412.78x | 4039256.57x | 4039256.57x |
| SciSparc Ltd. (SPRC)vs › | $245237.00 | N/A | N/A | N/A | N/A |
| Ridgetech, Inc. (RDGT)vs › | $827005.00 | N/A | 6.10x | 6.10x | 6.10x |
| Decoy Therapeutics Inc. (DCOY)vs › | $840509.00 | N/A | N/A | N/A | N/A |
EV/EBIT = Enterprise Value / EBIT (TTM)
Enterprise value to EBIT compares total company value to operating earnings, accounting for depreciation unlike EV/EBITDA.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
